Cargando…

Computed modeling of alternating electric fields therapy for recurrent glioblastoma

Tumor treating fields (TTFields) are alternating electric fields frequency tuned to 200 kHz for the treatment of recurrent glioblastoma. We report a patient treated with TTFields and determined the distribution of TTFields intracranially by computerized simulation using co-registered postgadolinium...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lok, Edwin, Hua, Van, Wong, Eric T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673996/ https://www.ncbi.nlm.nih.gov/pubmed/26311253 http://dx.doi.org/10.1002/cam4.519

Ejemplares similares

Analysis of physical characteristics of Tumor Treating Fields for human glioblastoma
por: Lok, Edwin, et al.
Publicado: (2017)

An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas
por: Wong, Eric T, et al.
Publicado: (2015)

Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation
por: Wong, Eric T, et al.
Publicado: (2015)

An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma
por: Swanson, Kenneth D., et al.
Publicado: (2016)

Role of alternative splicing signatures in the prognosis of glioblastoma
por: Xie, Zu‐cheng, et al.
Publicado: (2019)

Finite element analysis of Tumor Treating Fields in a patient with posterior fossa glioblastoma
por: Lok, Edwin, et al.
Publicado: (2020)

Glioblastoma recurrence correlates with NLGN3 levels
por: Liu, Rui, et al.
Publicado: (2018)

Rapid HER2 cytologic fluorescence in situ hybridization for breast cancer using noncontact alternating current electric field mixing
por: Watanabe, Shin‐nosuke, et al.
Publicado: (2020)

The natural history of intravascular lymphomatosis
por: Fonkem, Ekokobe, et al.
Publicado: (2014)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
por: Choi, Seung Won, et al.
Publicado: (2018)

Pseudoprogression as an adverse event of glioblastoma therapy
por: Balaña, Carmen, et al.
Publicado: (2017)

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
por: Nishikawa, Masahiro, et al.
Publicado: (2021)

Resolution of Cystic Enhancement to Add-On Tumor Treating Electric Fields for Recurrent Glioblastoma after Incomplete Response to Bevacizumab
por: Elzinga, Grace, et al.
Publicado: (2014)

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
por: Seyfrid, Mathieu, et al.
Publicado: (2022)

Computational Analysis of Tumor Treating Fields for Non-Small Cell Lung Cancer in Full Thoracic Models
por: Lok, Edwin, et al.
Publicado: (2023)

Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme
por: Marei, Hany E., et al.
Publicado: (2021)

COT-01 Experience of introducing alternating electric field therapy for an elderly glioblastoma patient living alone
por: Hayashi, Nobuhide, et al.
Publicado: (2020)

Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo
por: Voloshin, Tali, et al.
Publicado: (2016)

Alternating Electric Fields (TTFields) Activate Ca(v)1.2 Channels in Human Glioblastoma Cells
por: Neuhaus, Eric, et al.
Publicado: (2019)

The role of deep learning‐based survival model in improving survival prediction of patients with glioblastoma
por: Moradmand, Hajar, et al.
Publicado: (2021)

National cancer database analysis of outcomes in pediatric glioblastoma
por: Liu, Meng, et al.
Publicado: (2018)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

Electric field responsive nanotransducers for glioblastoma
por: Jain, Akhil, et al.
Publicado: (2022)

Bioinformatics analysis of potential core genes for glioblastoma
por: Zhang, Yu, et al.
Publicado: (2020)

MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics
por: Shea, Amanda, et al.
Publicado: (2016)

Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2
por: Bouchart, Christelle, et al.
Publicado: (2019)

HCK promotes glioblastoma progression by TGFβ signaling
por: Wang, Zhenlin, et al.
Publicado: (2020)

Glioblastoma Multiforme in the over 70's: “To treat or not to treat with radiotherapy?”
por: Glynn, Aisling M., et al.
Publicado: (2019)

Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial
por: Duerinck, Johnny, et al.
Publicado: (2021)

Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition
por: Yi, Renxin, et al.
Publicado: (2020)

Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme
por: Zhang, Botao, et al.
Publicado: (2019)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
por: Lee, Eudocia Q., et al.
Publicado: (2019)

Steroid treatment increases the recurrence of radiation-induced organizing pneumonia after breast-conserving therapy
por: Otani, Keisuke, et al.
Publicado: (2014)

Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages
por: Li, Guanzhang, et al.
Publicado: (2019)

Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma
por: Wong, Eric T, et al.
Publicado: (2014)

Positron emission tomography/computed tomography outperforms MRI in the diagnosis of local recurrence and residue of nasopharyngeal carcinoma: An update evidence from 44 studies
por: Li, Zhanzhan, et al.
Publicado: (2018)

Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes
por: Kessler, Tobias, et al.
Publicado: (2020)

Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma
por: Wong, E T, et al.
Publicado: (2015)

Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma
por: Wong, E T, et al.
Publicado: (2015)

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma
por: Marfia, Giovanni, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cjpgos1ssgpj6e6ttf0jsv1vt5